MCM
SLN

Massar Capital Management’s Silence Therapeutics SLN Stock Holding History

Massar Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,863
Closed -$115K – 210
2025
Q2 		$115K Buy
+19,863
New +$85.2K 0.09% 109

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Massar Capital Management's SLN Position: Q3 2025 in Review

Massar Capital Management sold out of Silence Therapeutics (SLN) in Q3 2025, closing a stake of 19,863 shares — an estimated $115K sold.

Massar Capital Management first reported a position in SLN in Q2 2025 and held it in 1 quarter. The position peaked at $115K in Q2 2025. 54 funds tracked by Wall St. Rank hold SLN as of Q3 2025.

  • Massar Capital Management reported no remaining Silence Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Massar Capital Management sold 19,863 Silence Therapeutics shares in Q3 2025, an estimated $115K.
  • Massar Capital Management first reported a position in Silence Therapeutics in Q2 2025 and held it in 1 quarter.
  • Massar Capital Management's Silence Therapeutics position peaked at $115K in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2025.

Based on Massar Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.